Terri B. Sebree - 26 Jan 2022 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc.

Role: President
Signature: /s/ Suzanne M. Hanlon, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 26 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 28 Jan 2022, 15:14:26 UTC
Next filing: 20 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZYNE	Common Stock	Award	$0	+85,000	+33%	$0.000000	346,146	26 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZYNE	Stock Option (right to buy)	Award	$0	+125,000		$0.000000	125,000	26 Jan 2022	Common Stock	125,000	$2.41	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock award will fully vest on January 26, 2024, subject to continued employment with the Company through the applicable vesting date.
F2	The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date.